Jump to content

bill

Administrators
  • Posts

    138
  • Joined

  • Last visited

  • Days Won

    9

bill last won the day on December 18 2021

bill had the most liked content!

Reputation

15 WALL STREET GURU

1 Follower

Recent Profile Visitors

1,118 profile views
  1. Bob wants to share the R107 formula with all his favorite investors. 2 to 3 medium (7" to 7-7/8" long) very ripe bananas, peeled (about 1 1/4 to 1 1/2 cups mashed) 1/3 cup (76g) butter, unsalted or salted, melted 1/2 teaspoon baking soda (not baking powder) 1 pinch salt 3/4 cup (150g) sugar (1/2 cup if you would like it less sweet, 1 cup if more sweet) 1 large egg, beaten 1 teaspoon vanilla extract. So there you have it. The true formula for R107. That was easy wasn't it?
  2. CLARITAS PHARMACEUTICALS INC CLAZF CLAZFOTC 0.0100 USD −0.0300 (−75.00%) Market Closed (as of Feb 16, 14:52 EST) https://www.tradingview.com/chart/?symbol=OTC%3ACLAZF
  3. China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint February 09, 2023 08:30 ET | Source: Bellerophon Therapeutics, Inc. WARREN, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial to support the registration of INOpulse® for the treatment of fibrotic interstitial lung disease (fILD) in China. The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon’s regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China. “We are delighted to expand our clinical program with the aim of bringing INOpulse to patients in need in Greater China,” said Peter Fernandes, Bellerophon’s Chief Executive Officer. “INOpulse has the potential to become the first therapy to treat an fILD population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension. This IND clearance further underscores the potential of INOpulse to improve activities of daily living and quality of life in patients with fILD, and supports the use of our novel primary endpoint, MVPA, which we are also utilizing in our ongoing Phase 3 REBUILD study in the U.S.” “We are excited to continue strengthening our partnership with Baylor BioSciences,” said Naseem Amin, Chairman of Bellerophon Therapeutics. “INOpulse has significant potential in treating various diseases associated with pulmonary hypertension and the clearance of this IND brings us one step closer to a new treatment option for the underserved fILD patient community in Greater China.” About Bellerophon Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com. Forward-looking Statements Any statements in this press release about Bellerophon’s future expectations, plans, and prospects, including statements about the clinical development of its product candidates, regulatory actions with respect to the Company’s clinical trials and expectations regarding the sufficiency of the Company’s cash balance to fund clinical trials, operating expenses and capital expenditures, and other statements containing the words “anticipate,” “believe,” “continue,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties relating to INOpulse®, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary or interim results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, the FDA’s substantial discretion in the approval process, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent Bellerophon’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. Contacts: LifeSci Advisors: Brian Ritchie (212) 915-2578 britchie@lifesciadvisors.com
  4. VANCOUVER, BC, July 20, 2022 /CNW/ - The following issues have been halted by IIROC: Company: Claritas Pharmaceuticals, Inc. TSX-Venture Symbol: CLAS All Issues: Yes Reason: Cease Trade Order Halt Time (ET): 7:45 am IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions For further information: For further information about IIROC's trading halt policy, please see Trading Halts & Timely Disclosure (https://www.iiroc.ca/news-and-publications/halts-and-resumptions) at www.iiroc.ca under the Halts and Resumptions tab. Please note that IIROC staff cannot provide any information about a specific halt beyond what is contained in this halt notice. For general information about IIROC, contact IIROC's Complaints and Inquiries team at inquiries@iiroc.ca or 1-877-442-4322 (Option 2). For company-related enquiries, contact the company directly. For more information on IIROC's regulatory role relating to halts and resumptions, including an FAQ, visit the Trading Halts & Timely Disclosure page. Search cease trade orders on the Canadian Securities Administrators website. Real-time surveillance provides IIROC with the ability to intervene in the market – including trading halts and varying or cancelling trades. Check out our video series on market volatility controls. Halts & Resumptions https://iiroc.mediaroom.com/index.php?year=2016&s=2429
  5. Claritas Pharmaceuticals, Inc. (CLAZF) Other OTC - Other OTC Delayed Price. Currency in USD https://finance.yahoo.com/quote/CLAZF/news/ Is this the same company trading on the U.S. stock market? Why has the stock symbol changed from CLAS to CLAZF TSXV MARKET Claritas Pharmaceuticals Inc (CLASh) Claritas Pharmaceuticals Inc. V.CLAS.H Primary Symbol: V.CLAS.H Alternate Symbol(s): CLAZF Kalytera Therapeutics Inc KALTF Why all the stock symbol changes? IIROC Trading Halt - CLAS 07/20/2022 | 07:50am EST VANCOUVER, BC, July 20, 2022 /CNW/ - The following issues have been halted by IIROC: Company: Claritas Pharmaceuticals, Inc. TSX-Venture Symbol: CLAS All Issues: Yes Reason: Cease Trade Order Halt Time (ET): 7:45 am IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions © Canada Newswire, source Canada Newswire English Funding Round•Jan 12, 2022 Claritas Pharmaceuticals raised $5,000,000 / Private Equity from Alumina Partners Next Earnings Date March 1st 2023 Claritas Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company developing a portfolio of pharmaceutical products in Canada. It develops new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering human therapeutics. $0.025 Fundamentals Snapshot (TSXV:CLAS.H) Last - 0.025 Beta - 2.89337 Year High - 0.19 Market Cap - 914.65k PB Ratio - 0.208 EPS - -0.21 Prev. Close - 0.025 Year Low - 0.025 Total Shares - 36.59m Shares Out - 37.79m
  6. bill

    Brave Theme

    Version 4.7.2

    0 downloads

    IPS Theme
    Free
  7. bill

    Menu Plus

    Version 1.2.2

    0 downloads

    This app allows you to change the IPS Default Menu to Advanced Dropdown Menu using tons of customization options.
    Free
  8. Aug 21, 2021 Using the triple moving average indicator, the commodity channel index (CCI), and the Awesome Oscillator (AO) to see if there is a turnaround coming soon for Claritas.
×
×
  • Create New...
  • Home
    Activities
    Sign In

    Sign In



    Search
    More
    ×